Myocardial and reproductive system toxicity of SCH 351591, a selective phosphodiesterase-4 inhibitor, in CD-1 mice

Toxicologic Pathology

Volumn 38, Issue 4, 2010, Pages 568-582

  Losco, Patricia E ^a   Poulet, Frederique M ^a   Kaminska Mcnamara, Grazyna Z ^a   Klein, Max F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cardiovascular system; Endocrine disrupters; Female reproduction; Mouse pathology; Ovary; Phosphodiesterase 4 inhibitor

Indexed keywords

ISOENZYME; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; PHOSPHODIESTERASE IV; AMINE OXIDE; PHOSPHODIESTERASE IV INHIBITOR; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CORPUS LUTEUM; DIESTRUS; DOSE RESPONSE; DRUG SELECTIVITY; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; ESTRUS CYCLE; FEMALE; FERTILITY; HISTOPATHOLOGY; MALE; MORPHOMETRICS; MOUSE; MYOCARDITIS; NONHUMAN; OVARY; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; TESTIS WEIGHT; UTERUS WEIGHT; ANATOMY AND HISTOLOGY; ANIMAL; ANIMAL EMBRYO; CHEMICALLY INDUCED; CYTOCHEMISTRY; DRUG EFFECTS; HEART; HEART DISEASE; HEART MUSCLE; INFERTILITY; ORGAN SIZE; PATHOLOGY; PROCEDURES; REPRODUCTION; TESTIS; TOXICITY; TOXICITY TESTING; UTERUS;

ANIMALS; CYCLIC N-OXIDES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DIESTRUS; EMBRYO, MAMMALIAN; FEMALE; HEART; HEART DISEASES; HISTOCYTOCHEMISTRY; INFERTILITY; MALE; MICE; MYOCARDIUM; ORGAN SIZE; OVARY; QUINOLINES; REPRODUCTION; TESTIS; TOXICITY TESTS, CHRONIC; UTERUS; PHOSPHODIESTERASE 4 INHIBITORS;

MUS;

EID: 77953673389     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310370463     Document Type: Article

References (41)

1. Ahern, W. and Dunnill, M. (1982). Preparation of tissues: sampling. In Morphometry, pp. 24-26. Edward Arnold, Baltimore, MD.
2. Badran, H. and Hermo, L. (2002). Expression and regulation of aquaporins 1, 8, and 9 in the testis, efferent ducts, and epididymis of adult rats and during postnatal development. J Androl 23, 358-373. (Pubitemid 34297325)
3. Beavo, J. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75, 725-748.
4. Bender, A. and Beavo, J. (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58, 488-520.
5. Bian, H., Zhang, J., Wu, P., Varty, L., Jia, Y., Mayhood, T., Hey, J., and Wang, P. (2004). Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. Biochem Pharmacol 68, 2229-2236.
6. Billah, M., Cooper, N., Minnicozzi, M., Warneck, J., Wang, P., Hey, J., Kreutner, W., Rizzo, C., Smith, S., Young, S., Chapman, R., Dyke, H., Shih, N., Piwinski, J., Cuss, F., Montana, J., Ganguly, A., and Egan, R. (2002). Pharmacology of N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2- (trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 302, 1-11.
7. Conti, M., Iona, S., Cuomo, M., Swinnen, J., Odeh, J., and Svoboda, M. (1995). Characterization of a hormone-inducible, high affinity adenosine 3ĝ€2-5ĝ€2cyclic monophosphate phosphodiesterase from the rat Sertoli cell. Biochemistry 34, 7979-7987.
8. Conti, M. (2002). Specificity of the cyclic adenosine 3ĝ€2,5ĝ€2-monophosphate signal in granulosa cell function. Biol Reprod 67, 1653-1661.
9. Conti, M., Richter, W., Mehats, C., Livera, G., Park, J., and Jin, C. (2003). Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278, 5493-5496.
10. Fischmeister, R., Castro, L., Abi-Gerges, A., Rochais, F., Jurevicius, J., Leroy, J. and Vandecasteele, G. (2006). Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99, 816-828.
11. Giembycz, M. (2000). Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here ? Drugs 59, 193-212.
12. Grover, A., Sairam, M., Smith, C., and Hermo, L. (2004). Structural and functional modifications of Sertoli cells in the testis of adult follicle-stimulating hormone receptor knockout mice. Biol Reprod 71, 117-129.
13. Heaslip, R. and Evans, D. (1995). Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur J Pharmacol 286, 281-290.
14. Jin, S.-L., Richard, F., Kuo, W.-P., DErcole, A. and Conti, M. (1999). Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. PNAS 96, 11998-10003.
15. Jones, H., Macpherson, A., Betton, G., Davis, A., Siddall, R., and Greaves, P. ( 2003 )., Endothelin antagonist-induced coronary and systemic arteritis in the Beagle dog. Toxicol Pathol 31, 263-272.
16. Joseph, E., Rees, J., and Dayan, A. (1996). Mesenteric arteriopathy in the rat induced by phosphodiesterase III inhibitors: an investigation of morphological, ultrastructural, and hemodynamic changes. Toxicol Pathol 24, 436-450.
17. Jurevicius, J. and Fischmeister, R. (1996). cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by β-adrenergic agonists. Proc Natl Acad Sci U S A 93, 295-299.
18. Larson, J., Pino, M., Geiger, L., and Simeone, C. (1996). The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 78, 44-49.
19. Lehnart, S., Wehrens, X., Reiken, S., Warrier, S., Belevych, A., Harvey, R., Richter, W., Jin, S., Conti, M., and Marks, A. (2005). Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123, 25-35.
20. Li, S., and Davis, B. (2007). Evaluating rodent vaginal and uterine histology in toxicity studies. Birth Defects Res (Part B) 80, 246-252.
21. Losco, P., Evans, E., Barat, S., Blackshear, P., Reyderman, L., Fine, J., Bober, L., Anthes, J., Mirro, E., and Cuss, F. (2004). The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys. Toxicol Pathol 32, 295-308.
22. Lugnier, C. and Komas, N. (1993). Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J 14 (Suppl I). 141-148.
23. Matsumoto, T., Kobayashi, T. and Kamata, K. (2003). Phosphodiesterases in the vascular system. J Smooth Muscle Res 39, 67-86.
24. McDuffie, J., Yu, X., Sobocinski, G., Song, Y., Chupka, J. and Albassam, M. (2006). Acute coronary artery injury in dogs following administration of CI-1034, an endothelin A receptor antagonist. Cardiovasc Toxicol 6, 25-38.
25. Mesfin, G.M., Piper, R.C., DuCharme, D.W., Carlson, R.G., Humphrey, S.J., and Zins, G.R. (1989). Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol Pathol 17, 164-181.
26. Omori, K., and Kotera, J. (2007). Overview of PDEs and their regulation. Circ Res 100, 309-327.
27. OShaughnessy, P., Morris, I., Huhtaniemi, I., Baker, P. and Abel, M. (2009). Role of androgen and gonadotrophins in the development and function of the Sertoli cells and Leydig cells: data from mutant and genetically modified mice. Mol Cell Endocrinol 306, 2-8.
28. Palacios, J., Beleta, J., and Segarra, V. (1995). Second messenger systems as targets for new therapeutic agents: focus on selective phosphodiesterase inhibitors. Il Farmaco 50, 819-827.
29. Paruthiyil, S., El Majdoubi, M., Conti, M. and Weiner, R. (2002). Phosphodiesterase expression targeted to gonadotropin-releasing hormone neurons inhibits luteinizing hormone pulses in transgenic rats. PNAS 99, 17191-17196.
30. Perry, S., Baillie, G., Kohout, T., McPhee, I., Magiera, M., Ang, K., Miller, W., McLean, A., Conti, M., Houslay, M. and Lefkowitz, R. (2002). Targeting of cyclic AMP degradation to β2-adrenergic receptors by β2-arrestins. Science 298, 834-836.
31. Russell, L., Ettlin, R., Sinha Hikim, A., and Clegg, E. (1990). Histological and Histopathological Evaluation of the Testis. p. 32. Cache River Press, Clearwater, FL.
32. Sakakibara, H., Conti, M., and Weiner, R. (1998). Role of phosphodiesterases in the regulation of gonadotropin-releasing hormone secretion in GT1 cells. Neuroendocrinology 68, 365-373.
33. Setchell, B. and Sharpe, R. (1981). Effect of injected human chorionic gonadotrophin on capillary permeability, extracellular fluid volume and the flow of lymph and blood in the testes of rats. J Endocrinol 91, 245-254.
34. Slim, R., Song, Y., Albassam, M., and Dethloff, L. (2003). Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats. Toxicol Pathol 31, 638-645.
35. Vogel, B., Kolopp, M., de Brugerolle de Fraissinette, A., Singer, T., Ettlin, R., Birnbaum, I., and Cordier, A. (1999). Minipigs in safety assessment of a phosphodiesterase type IV inhibitor for the treatment of inflammatory skin diseases. Toxicologist 48, 323.
36. Weiner, R. and Charles, A. (2001). Regulation of gonadotropin-releasing hormone release by cyclic AMP signaling pathways. Growth Horm IGF Res (Suppl A). S9 - S15.
37. Yang, F., Kawedia, J. and Menon, A. (2003). Cyclic AMP regulates aquaporin 5 expression at both transcriptional and post-transcriptional levels through a protein kinase A pathway. J Biol Chem 278, 32173-32180.
38. Yuan, Y. (1991). The female reproductive system. In: Handbook of Toxicologic Pathology (W. M. Haschek and C. G. Rousseaux, eds.). pp. 914-924, Academic Press, Inc., New York, NY.
39. Zaccolo, M. and Pozzan, T. (2002). Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 295, 1711-1715.
40. Zhang, J., Herman, E., Knapton, A., Chadwick, D., Whitehurst, V., Koerner, J., Papoian, T., Ferrans, V., and Sistare, F. (2002). SK&F 95654-induced acute cardiovascular toxicity in Sprague-Dawley rats-histopathologic, electron microscopic, and immunohistochemical studies. Toxicol Pathol 30, 28-40.
41. Zhang, J., Snyder, R., Herman, E., Knapton, A., Honchel, R., Miller, T., Espandiari, P., Goodsaid, F., Rosenblum, I., Hanig, J., Sistare, F., and Weaver, J. (2008). Histopathology of vascular injury in Sprague-Dawley rats treated with phosphodiesterase IV inhibitor SCH 351591 or SCH 534385. Toxicol Pathol 36, 827-839.